"The Barclays analysts said Gilenya, recently launched in the United States, had 23 percent of new written prescription starts in November among neurologists, according to data from pharmaceuticals industry research firm ImpactRx."
New scripts at 23%. Wow.
That has to affect Teva and potentially MNTA very strongly, as well as BIIB and others. Or am I missing something?
News 
Market Data 
Discover 
